



Dear Healthcare Professionals,

**Important Update: Reclassification of naproxen – 6month extension for Naprogesic from published dates**



November 18, 2024

Due to delays in implementation of updated packaging for Naprogesic 12pack and 24pack to new classification, **Bayer has requested a 6 month extension from the published dates.**

Bayer New Zealand Limited

Extension transition dates will enable stock bearing superceded labelling to be sold through **wholesaler level until end June 2025** and sold through **retailer level until end September 2025.**

74 Taharoto Road  
Takapuna  
Auckland 0622  
New Zealand

Background information published by Medsafe:

The Minister of Health's Delegate has considered the recommendation and has decided to reclassify medicines containing naproxen to:

Postal Address  
PO Box 2825  
Auckland 1140  
New Zealand

- *Prescription: except when specified elsewhere in this schedule.*
- *Restricted (pharmacist only): in solid dose forms in medicines containing 250 milligrams or less per dose form in packs containing not more than 30 tablets or capsules and with a recommended daily dose of more than 750 milligrams per day.*
- *Pharmacy only: in solid dose forms in medicines containing 250 milligrams or less per dose form in packs containing not more than 30 tablets or capsules and with a recommended daily dose of not more than 750 milligrams per day.*

[www.bayer.co.nz](http://www.bayer.co.nz)

**Medical enquiries**

Please direct any medical enquiries to Bayer by email at [medinfo.anz@bayer.com](mailto:medinfo.anz@bayer.com) or Phone: 0800 229 376

Yours sincerely,

*Anne McArthur*

Anne McArthur  
Head of Regulatory Affairs  
Bayer Consumer Health  
ANZ